CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on Carbacitabin, a new compound aimed at treating acute myeloid leukemia and myelodysplastic syndrome. It offers improved stability and efficacy, particularly for high-risk patients, addressing a critical gap in current treatment options.
The current treatment landscape for leukemia, particularly concerning AML (acute myeloid leukemia) and MDS (myelodysplastic syndrome), is constrained by the instability of hypomethylating agents which are regularly used in elderly, medically non-fit patients (high-risk).
This instability restricts their spectrum of application, leaving a significant gap in effective treatment options.
Despite research into alternative therapeutic approaches the need for a mild treatment option with high success…
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
